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ABSTRACT  21 
The immunomodulatory, anti-inflammatory and anti-proliferative properties of vitamin D have laid 22 
the basis for a possible function of this prohormone in the pathogenesis of endometriosis. The aim 23 
of this case-control study was investigating vitamin D status, by measuring 25-hydroxyvitamin D 24 
[25(OH)D] serum levels, in women with and without endometriosis. Only Italian women of 25 
Caucasian origin aged between 18 and 45 years were deemed eligible. Enrollment was limited to 26 
the period October-May. Cases and controls were matched for month of recruitment, and 27 
secondarily for age and parity. Overall, 434 women were enrolled (endometriosis n = 217; controls 28 
n = 217). The group of cases included 127 women with ovarian endometrioma and 90 patients with 29 
deep endometriosis. Mean ± SD levels of 25(OH)D in women with and without endometriosis were 30 
17.9 ± 7.0 ng/ml and 18.4 ± 7.6, respectively (P = 0.46). Analyzing the two endometriosis sub-31 
group separately no statistically significant differences emerged (18.7 ± 7.4 ng/ml in deep 32 
endometriosis group versus 17.3 ± 6.6 ng/ml in women with ovarian endometrioma; P = 0.14). 33 
Comparing the sub-group of women with deep endometriosis with paired controls no differences 34 
occurred (18.7 ± 7.4 ng/ml versus 18.5 ± 7.7 ng/ml, P = 0.80). Similar data emerged when 35 
performing the same analysis for ovarian endometriomas (17.4 ± 6.6 ng/ml versus 18.3 ± 7.6 ng/ml, 36 
P = 0.23). The results of the present case-control study do not support an association between serum 37 
vitamin D levels and different phenotypes of endometriosis.  38 
KEY WORDS: endometriosis; vitamin D; 25-hydroxyvitamin D; deep endometriosis; ovarian 39 
endometrioma 40 
41 
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INTRODUCTION 42 
The immunomodulatory, anti-inflammatory and anti-proliferative properties of vitamin D have laid 43 
the basis for a possible function of this prohormone in the pathogenesis of endometriosis.1 In fact, a 44 
dysfunction of the immune system responsible for a state of chronic inflammation has been claimed 45 
to play a role in the multifactorial pathogenesis of the disease.2 Indeed, endometriosis is 46 
characterized by a reduced T-cell cytotoxicity, a functional deficit of natural-killer lymphocytes and 47 
higher concentration of activated macrophages in the peritoneal fluid, which generate a cascade of 48 
cytokines and vascular endothelial growth factors favoring the proliferation of endometrial cells and 49 
angiogenesis.3,4 Along with this theory, abnormal levels of pro-inflammatory cytokines have been 50 
detected in the peritoneal fluid and serum of affected women,5 and murine models suggested the 51 
potential role of interleukin-6 and tumor necrosis factor α through their effect on inflammatory 52 
angiogenesis.6  53 
Moreover, vitamin D receptor is expressed in ovarian tissue, endometrium, and fallopian 54 
epithelial cells,1 and both eutopic and ectopic endometrium express the enzyme 1α-hydroxylase, 55 
responsible for the conversion of 25-hydroxyvitamin D [25(OH)D] into the biologically active form 56 
of vitamin D, calcitriol.7 Of relevance here is a recent study in a murine model of endometriosis 57 
showing that calcitriol is able to both prevent ectopic implantation of endometrium and to reduce 58 
already established lesions.8 Finally, numerous in vitro and in vivo studies have demonstrated that 59 
vitamin D deficiency could increase the risk of several cancer and autoimmune diseases, which tend 60 
both to be more common in women with endometriosis.9-11 61 
 Given this background, the potential role of vitamin D is of increasing interest and, in the 62 
last two decades, various studies have investigated the relation between endometriosis and vitamin 63 
D serum levels, with inconsistent results (Table 1).12-17 Therefore, the influence of vitamin D on 64 
endometriosis development and progression remains to be clarified. To shed more light on this 65 
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potential association, we have compared serum concentrations of 25(OH)D in a large case-control 66 
study of women with and without endometriosis.   67 
MATERIAL AND METHODS 68 
This case-control study was performed in an academic hospital, the Fondazione Ca’ Granda 69 
Ospedale Maggiore Policlinico that includes a tertiary referral center for the study and management 70 
of endometriosis. Participants were recruited during the period October 2014 – January 2017. Only 71 
Italian women of Caucasian origin aged between 18 and 45 years were deemed eligible. Cases were 72 
women with a surgical diagnosis of endometriosis in the previous 24 months or with a current non-73 
surgical diagnosis of endometriosis. Non-surgical diagnoses were based on previously published 74 
criteria.18-21 Affected women were sub-categorized in two groups, namely deep invasive 75 
endometriosis and ovarian endometrioma. The former included women with rectovaginal plaques, 76 
bladder detrusor nodules, bowel lesions, intrinsic ureteral endometriosis, and deep endometriosis 77 
infiltrating the pouch of Douglas and parametria. Cases with iatrogenic, post-Caesarean bladder 78 
detrusor endometriosis were excluded. In the same time span, women attending our outpatient 79 
clinics for periodic well-woman visits, contraception, cervical cancer screening program, or 80 
attending the blood bank of our hospital for blood donation, and without a previous clinical or 81 
surgical diagnosis of endometriosis, were enrolled as control group. Endometriosis was excluded 82 
based on gynecological history, pelvic transvaginal ultrasound, gynecological bimanual 83 
examination and visual inspection of the posterior vaginal fornix. 84 
Patients reporting malignancy, uterine leiomyomas, hypertension, diabetes, multiple 85 
sclerosis, autoimmune disorders, and coronary, hepatic, or renal diseases were excluded from both 86 
study groups. Other exclusion criteria include vitamin D supplementation and full body sun 87 
exposure during the month before study enrollment. Cases and controls were matched for month of 88 
recruitment, and secondarily for age and parity. Moreover, to prevent the impact of seasonality and 89 
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the likely inter-participant variable degree of sun exposure, the recruitment was limited to the 90 
period October-May.  91 
In women who agreed to participate a blood sample was drawn. Blood samples were allowed to clot 92 
at room temperature and then centrifuged at 2,000 g for 10 minutes. The resulting serum was stored 93 
at -20 °C until assayed. The quantitative detection of total 25(OH)D levels were obtained using a 94 
commercially available kit based on a chemiluminescence technology (DiaSorin, Inc. Corp., 95 
Stillwater, MN, USA). The assessments were performed in three distinct experiments thawing a 96 
similar number of blood samples from matched case and controls. The intra- and interassay 97 
coefficients of variations were 10% and 15%, respectively. The biologists engaged in the 25(OH)D 98 
assessment were blinded to the condition of the patients and to the study aims. 99 
Data were collected on standardized forms including demographic information and clinical 100 
characteristics. In addition, enrolled women filled out a detailed questionnaire evaluating current 101 
and previous sun exposure habits, phenotypic characteristics, and skin phototype; the latter has been 102 
assessed according to the Fitzpatrick classification,22 that reflects, to some extent, the degree of skin 103 
color intensity and the extent of skin sensitivity to damage generated by ultraviolet radiation. 104 
In the current study, the concentration of vitamin D is expressed as ng/ml, and severe 105 
deficiency, deficiency, insufficiency, and sufficiency were defined when values were <10, <20, ≥20 106 
- <30, and ≥30 ng/ml, respectively.23 The competent Institutional Review Board approved the study, 107 
and patients gave written informed consent (Comitato di Etica Milano Area B; determination 108 
#1940/2014, approval date September 5, 2014).  109 
 Data were archived using Excel 2003 (Microsoft Corporation, Redmond, Washington, 110 
U.S.A.) and exported in SPSS 18.0 (SPSS, Inc, Chicago, IL, U.S.A.) for statistical analysis. Data 111 
were compared using unpaired or paired Student-t test, Fisher Exact test or McNemar test, as 112 
appropriate. P values below 0.05 were considered statistically significant. As previously adopted by 113 
                                                                                                                                 Buggio et al.,  
 
6 
Paffoni et al.,24 the choice of the sample size was calculated based on an expected serum 114 
concentration of 25(OH)D in controls of 20.4±11.8 ng/mL.13 A difference of -20% in serum 115 
25(OH)D in women with endometriosis was deemed clinically important. Setting type I and II 116 
errors to 0.05 and 0.05, the calculated number of women to be recruited was 434, 217 per study 117 
group. 118 
RESULTS 119 
Recruitment continued until the pre-planned number of participants was reached (endometriosis n = 120 
217; controls n = 217). The group of cases included 127 women with ovarian endometriomas and 121 
90 patients with deep lesions. The deep endometriosis group comprised 51 patients with 122 
rectovaginal endometriotic plaques, 18 with full-thickness bladder detrusor nodules, 11 with deep 123 
lesions infiltrating the pouch of Douglas and parametria, 7 with full-thickness bowel lesions, and 3 124 
with intrinsic ureteral endometriosis. Baseline clinical and gynecological characteristics of cases 125 
and controls are shown in Table 2. The distribution of the demographic variables is similar between 126 
the two study groups. Regarding gynecological characteristics, parity did not differ (as expected 127 
based on the study design) whereas, as predictable, use of hormonal therapies and pain symptoms 128 
(dysmenorrhea, deep dyspareunia, non-menstrual pelvic pain, and dyschezia) were significantly 129 
more frequent in women with endometriosis (Table 2). 130 
 Serum levels of 25(OH)D were 17.9 ± 7.0 ng/ml in the endometriosis group and 18.4 ± 7.6 131 
ng/ml in the control group (P = 0.46). The monthly distribution of serum 25(OH)D in the two study 132 
groups is illustrated in Figure 1. When analyzing the two endometriosis sub-groups separately, no 133 
statistically significant differences emerged (18.7 ± 7.4 ng/ml in the deep endometriotic lesions 134 
group versus 17.3 ± 6.6 ng/ml in the ovarian endometrioma group; P = 0.14). At subgroup analysis, 135 
no statistically significant differences were observed when comparing separately women with deep 136 
endometriotic lesions and those with ovarian endometriomas with their matched controls (18.7 ± 137 
7.4 ng/ml versus 18.5 ± 7.7 ng/ml, P = 0.80 and 17.4 ± 6.6 ng/ml versus 18.3 ± 7.6 ng/ml, P = 0.23, 138 
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respectively). In addition, no statistically significant differences emerged after subdividing 139 
25(OH)D serum concentrations of the two study groups into the four categories (severe deficiency, 140 
deficiency, insufficiency, and sufficiency) (P = 0.29; Table 3). A total of 13% of women with deep 141 
endometriotic lesions (n = 12) had severely deficient 25(OH)D serum levels, 49% (n = 44) deficient 142 
concentrations, 31% (n = 28) insufficient levels, and, 7% (n = 6) adequate levels; these figures were 143 
not statistically significantly different from those observed in their matched controls (P = 0.50). The 144 
corresponding frequencies for women with ovarian endometriomas were, 16% (n = 20), 68% (n = 145 
53), 28% (n = 35), and 3% (n = 4), respectively, again without statistically significant differences 146 
with their matched controls (P = 0.38). 147 
 The phenotypic characteristics, current and previous sun exposure habits, and cutaneous 148 
reaction to UV are shown in Table 4. No statistically significant differences emerged between the 149 
two study groups. Current and past global UV exposure were comparable between women with and 150 
without the disease, being 23.2 ± 18.7 days and 20.9 ± 14.1 days during adulthood (P = 0.14) and 151 
43.3 ± 35.3 days and 45.9 ± 32.3 days during adolescence (P = 0.44), respectively. The median 152 
[interquartile range, IQR] duration of last sun exposure prior to enrollment was 14 [7-15] days in 153 
endometriosis group and 10 [7-15] days in control group (P = 0.75), whereas the number of days 154 
elapsed between last UV exposure and recruitment was, respectively, 195 [135-236]   in the former 155 
group and 202 [142-258] in the latter group (P = 0.26). 156 
COMMENT 157 
In this study, statistically significant differences in 25(OH)D serum levels were not observed when 158 
comparing women with and without endometriosis. In addition, no differences emerged after 159 
subdividing patients into the phenotypic categories of deep endometriotic lesions and ovarian 160 
endometriomas. Lacks of differences in UV exposure habits further support our findings. In both 161 
study groups, median 25(OH)D serum concentrations were below the limit of normalcy established 162 
by the Endocrine Society guidelines.23 This questions the validity of this categorization scheme, at 163 
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least in the Northern Italian context, and supports the opportunity of reconsidering its 164 
discriminatory cut-off limits.25 Indeed, particularly in our Mediterranean country, an insufficient 165 
degree of sun exposure may not be deemed the cause of low 25(OH)D serum concentrations. 166 
 Our findings are in line with those obtained by Agic et al.,14 whereas in other observational 167 
studies higher13 or lower15-17 vitamin D serum levels were observed in women with endometriosis 168 
(Table 1). Noteworthy, the present results are also at odds with previous evidence from our own 169 
group.13 Among the reasons that may explain these inconsistencies, differences in study design and 170 
sample size presumably play a role. Unfortunately, studying the impact of vitamin D on the 171 
pathogenesis of endometriosis is methodologically challenging. Confounding may bias 172 
observational studies, and the disease itself might also theoretically lower vitamin D concentrations 173 
(reverse causality bias).26 Indeed, low 25(OH)D serum levels could result from the inflammatory 174 
process, peculiar of endometriotic disease.27 Environmental factors, such as sun exposure, smoke, 175 
obesity and dietary intake also influence the levels of vitamin D.28  176 
 To disentangle whether vitamin D may play a role in the pathogenesis of endometriosis, it 177 
would be more interesting to test women before disease development, i.e. in the adolescent period 178 
or even earlier,29 rather than when the disease is diagnosed at a later age. To this aim, a long-term 179 
cohort design would be more appropriate, but also much more costly and cumbersome to conduct. 180 
In order to obtain some information on this aspect, we included in our study some questions 181 
regarding UV exposure during adolescence and, again, we failed to show any difference between 182 
the study groups. This type of evidence is however exposed to a significant risk of recall bias.  183 
 One of the advantages of our study design is represented by the large sample size; in fact, in 184 
none of the previously published observational studies, more than 400 subjects had been enrolled. 185 
Only the study from Harris et al.15 reporting on the Nurses’ Health Study II included a larger 186 
sample size but the study exclusively focused on the estimated nutritional intake of the vitamin that 187 
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generally represents only 10% of the human needs. In humans, the most relevant source of vitamin 188 
D is provided by UV exposure.9,30.31 189 
 Matching cases and controls for month of recruitment allowed to elude the relevant potential 190 
confounding effect of seasonality. Moreover, to prevent the impact of variable sun exposure, we 191 
decided to limit enrollments to the October – May period and to exclude the women that reported a 192 
global UV radiations exposure in the month before blood collection. Noteworthy, this latter 193 
exclusion criterion should not have biased our results considering that only a minority of patients 194 
were excluded on this basis, and this proportion did not differ between the study groups (less than 195 
5% in both groups). In addition, women with disease potentially related to vitamin D deficiency, 196 
such as uterine leiomyomas, cancer, multiple sclerosis or taking vitamin D supplements were 197 
excluded from the study. Finally, the two study groups had similar basal characteristics (geographic 198 
origin, BMI, cigarette smoke, phenotypic and sun exposure characteristics).  199 
As for any case-control study, the choice of controls may be cause of concern. In our study, 200 
we decided to include women without known endometriosis presenting to the gynecologic unit for 201 
routine well-woman visit, contraception, cervical cancer screening or to the blood bank of our 202 
hospital for blood donation. Endometriosis was ruled out based on gynecological and 203 
ultrasonographic examination but we cannot exclude to have inadvertently included some cases 204 
among controls. However, the impact of this potential inaccuracy would be presumably modest, 205 
given the limited prevalence of asymptomatic endometriosis in the general population.32 Moreover, 206 
mis-diagnoses are more likely for early superficial peritoneal endometriosis, a condition of doubtful 207 
clinical relevance.33   208 
 Another potential limitation of our study could be represented by the lack of a food 209 
questionnaire investigating the dietary habits of recruited women. However, as mentioned earlier, 210 
vitamin D reserve is mostly due to sunlight exposure (90%) rather than dietary intake (10%).9  211 
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In conclusion, the results of the present case-control study do not support an association 212 
between serum vitamin D levels and endometriosis. If these findings will be confirmed the potential 213 
role of vitamin D in the development of endometriosis should be challenged.214 
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FIGURE LEGEND 306 
Figure 1. Serum levels of 25(OH)D in women with endometriosis (red columns) and in control 307 
participants (blue columns) according to month of recruitment. None of the differences is 308 
statistically significant.309 
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Table 1. List of studies evaluating 25(OH)D serum levels in women with and without endometriosis (literature data 1990-2017). 
 
Source Year Country Study design 
N° of patients enrolled 
(endometriosis; controls) 
Dosage 
evaluation 
Mean ± DS 25(OH)D serum 
levels (endometriosis; 
controls) 
P 
Hartwell, et al.12 1990 Denmark Case-control 155 (n = 42; n =113) Serum 
32.2 ± 0.6 ng/ml;                                       
30.5 ± 14.1 ng/ml 
0.43 
Somigliana et al.,13   2007 Italy 
Cross-sectional in women 
scheduled for gynecologic 
surgery 
140 (n = 87; n = 53) Serum 
24.9 ± 14.8 ng/ml;                                  
20.4 ± 11.8 ng/ml 
0.05 
Agic et al.,14 2007 Germany 
Case-control in women 
scheduled for benign 
gynecologic surgery 
79 (n = 46; n = 33) Serum 
25.7 ± 2.1 ng/ml;                                    
22.6 ± 2.0 ng/ml 
0.31 
Harris et al.,15 2013 
United 
States 
Prospective cohort study 
(Nurses’ Health Study II) 
70.556  
(n = 1385; n = 69.171) 
Predicted serum 
levels based on 
daily food intake 
Predicted plasma 25(OH)D 
levels were inversely associated 
with endometriosis risk 
0.004a 
Miyashita et al.,16  2016 Japan 
Cross-sectional in women 
scheduled for laparoscopy 
for endometriosis or benign 
ovarian tumor (patients were 
negative for uterine 
fibroids). 
76 (n = 39b; n =37) Serum 
Severe endometriosis: 
 17.2 ± 1.1 ng/ml;c 
 
Mild endometriosis:  
21.5 ± 1.4 ng/ml; 
<0.01c 
Controls: 21.8 ± 1.3 ng/ml <0.05c 
Anastasi et al.,17 2017 Italy Case-control 194 (n = 104; n = 90) Serum 
 
21.3 ± 8.9 ng/ml;                                   
32.3 ± 2.7 ng/ml 
<0.01 
 
25(OH)D = 25-hydroxy vitamin D        
a Women in the highest quintile of predicted vitamin D level had a 24% lower risk of endometriosis than women in the lowest quintile (rate ratio = 0.76, 95% 
confidence interval: 0.60, 0.97; p trend = 0.004). 
b Mild endometriosis (n = 17, stage 1 and 2), severe endometriosis (n = 22; stage 3 and 4) 
c Serum levels of 25(OH)D in samples from patients with severe endometriosis were significantly lower than those detected in samples from women with 
mild endometriosis (P < 0.01) and controls (P <0.05)
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Table 2. Baseline demographic and clinical characteristics of participants in the two study groups. 
 
Characteristics Endometriosis Controls P 
    
Age (years) 34,2 ± 6,5 33,2 ± 6,5 0.14 
Italian area of origin    
North 175 (81%) 164 (76%) 0.31 
Center 11 (5%) 10 (4%)  
South 31 (14%) 43 (20%)  
BMI (Kg/m2) 21,7 ± 3,3 22,0 ± 3.0 0.29 
Smoking    
Yes 57 (26%) 59 (27%) 0.47 
No  143 (66%) 134 (62 %)  
Previous smoker 17 (8%) 24 (11%)  
Marital status    
Married 77 (35%) 60 (28%) 0.10 
Unmarried 140 (65%) 157 (72%)  
Working status   0.13 
Employed 181 (83%) 193 (89%)  
Unemployed (or student) 36 (17%) 21 (11%)  
Previous deliveries   0.67 
None 155 (72) 159 (73)  
1 33 (15) 35 (16)  
≥ 2 29 (13) 23 (11)  
Hormonal therapies   <0.001 
None 89 (41) 153 (71)  
Estroprogestins 61 (28) 60 (28)  
Progestins 63 (29) 4 (2)  
GnRH analogues 4 (2) 0 (0)  
Dysmenorrhea a 112 (52) 42 (20) <0.001 
Dyspareunia a 79 (36) 7 (3) <0.001 
Non menstrual pelvic pain a 71 (33) 11 (5) <0.001 
Dyschezia a 48 (22) 7 (3) <0.001 
        
 
BMI = body mass index. 
Data are expressed as mean ± SD or number (percentage). 
a The presence of pain symptoms was determined using the NRS (numeric rating scale) and 
considering the symptom present if NRS was >5. 
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Table 3. Categorization of serum concentrations of 25(OH)D in women with and without 
endometriosis. 
____________________________________________________________________________ 
Serum levels (ng/ml)  Endometriosis (%)  Controls (%)  P 
____________________________________________________________________________ 
            0.29 
Severe deficiency (<10 ng/ml)  32 (15)       31 (14) 
Deficiency (10-19.9 ng/ml)            112 (52)     107 (49) 
Insufficiency (20-29.9 ng/ml)             63 (29)                             60 (28) 
Sufficiency (≥30 ng/ml)              10 (  4)        19 ( 9) 
 
____________________________________________________________________________ 
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Table 4. Phenotypic characteristics, sun exposure habits and cutaneous reaction to UV in patients 
with endometriosis and in control participants. 
 
 
Endometriosis (%) 
(n = 217) 
Controls (%) 
(n = 217) 
Ptrend 
    
Hair color   0.26 
Black 5 (2) 6 (3)  
Dark brown 107 (49) 97 (44)  
Light brown 77 (36) 80 (37)  
Blonde 25 (12) 28 (13)  
Red 3 (1) 6 (3)  
 
Skin phototype    0.45 
Type 1 9 (4) 8 (4)  
Type 2 49 (23) 39 (18)  
Type 3 86 (39) 96 (44)  
Type 4 49 (23) 52 (24)  
Type 5 24 (11) 17 (8)  
Type 6 0 (0) 5 (2)  
 
Sun exposure during adolescence (16-18 aa)  0.42 
Never 1 (1) 0 (0)  
Rare 15 (6) 19 (9)  
Occasional 82 (38) 82 (38)  
Frequent 82 (38) 88 (40)  
Very frequently 37 (17) 28 (13)  
Sun exposure during work activity  0.11 
Never 152 (70) 165 (76)  
Rare 35 (16) 29 (13)  
Occasional 19 (9) 18 (8)  
Frequent 8 (4) 4 (2)  
Very frequently 3 (1) 1 (1)  
Sun exposure during leisure  0.23 
Never 5 (2) 1 (1)  
Rare 38 (17) 39 (18)  
Occasional 95 (44) 120 (55)  
Frequent 69 (32) 52 (24)  
Very frequently 10 (5) 5 (2)  
 
Use of UV tanning lamps during 
adolescence   0.85 
Si 112 (52) 115 (53)  
No 105 (48) 102 (47)  
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Endometriosis (%) 
(n = 217) 
Controls (%) 
(n = 217) 
Ptrend 
 
 
 
Current use of UV tanning lamps 
 
 
 
 
 
0.81 
Yes 44 (20) 41 (19)  
No 173 (80) 176 (81)  
Cutaneous reaction after 1h of sun exposure  0.36 
None 68 (31) 63 (29)  
Occasional burns 116 (54) 113 (52)  
Always burns 33 (15) 41 (19)  
Do you like to catch the sun?    1.00 
Yes 168 (77) 169 (78)  
No 49 (23) 48 (22)  
Use of protective tanning cream    0.73 
Never 11 (5) 8 (4)  
Occasionally 51 (24) 61 (28)  
Always 155 (71) 148 (68)  
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